

# Combination Therapy with Lopinavir/Ritonavir, Ribavirin, and Zalcitabine for Severe Acute Respiratory Syndrome

Antiviral Therapy

21, 455-459

DOI: 10.3851/imp3002

Citation Report

#	ARTICLE	IF	CITATIONS
1	Treatment strategies for Middle East respiratory syndrome coronavirus. <i>Journal of Virus Eradication</i> , 2016, 2, 1-4.	0.3	28
2	Middle East respiratory syndrome coronavirus: current situation and travel-associated concerns. <i>Frontiers of Medicine</i> , 2016, 10, 111-119.	1.5	19
3	A review of treatment modalities for Middle East Respiratory Syndrome. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3340-3350.	1.3	87
5	SARS and MERS: recent insights into emerging coronaviruses. <i>Nature Reviews Microbiology</i> , 2016, 14, 523-534.	13.6	2,752
6	Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model. <i>Virus Research</i> , 2017, 228, 7-13.	1.1	68
7	Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV). <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 269-275.	2.0	45
8	Middle East respiratory syndrome coronavirus: five years later. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 901-912.	1.0	29
9	Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review. <i>Journal of Infection and Public Health</i> , 2018, 11, 9-17.	1.9	111
10	Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon- $\beta$ (MIRACLE trial): study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 81.	0.7	221
11	Uso de ribavirina en virus distintos de la hepatitis C. Una revisión de la evidencia. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 602-608.	0.3	18
12	Use of ribavirin in viruses other than hepatitis C. A review of the evidence. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2019, 37, 602-608.	0.2	6
13	A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). <i>Travel Medicine and Infectious Disease</i> , 2019, 30, 9-18.	1.5	103
14	Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections. <i>Frontiers in Microbiology</i> , 2019, 10, 1327.	1.5	88
15	Broad-spectrum coronavirus antiviral drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2019, 14, 397-412.	2.5	168
16	Identification and design of novel small molecule inhibitors against MERS-CoV papain-like protease via high-throughput screening and molecular modeling. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 1981-1989.	1.4	23
17	MERS coronavirus outbreak: Implications for emerging viral infections. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 93, 265-285.	0.8	104
18	Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. <i>Nature Communications</i> , 2020, 11, 222.	5.8	1,376
19	Drug Weaponry to Fight Against SARS-CoV-2. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 204.	1.6	2

#	ARTICLE	IF	CITATIONS
20	COVID-19 outbreak: Challenges in pharmacotherapy based on pharmacokinetic and pharmacodynamic aspects of drug therapy in patients with moderate to severe infection. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2020, 49, 763-773.	0.8	19
21	Potential Therapeutic Options for COVID-19. <i>Infectious Microbes &amp; Diseases</i> , 2020, 2, 89-95.	0.5	0
22	Novel hybrid antiviral VTRRT-13V2.1 against SARS-CoV2 main protease: retro-combinatorial synthesis and molecular dynamics analysis. <i>Heliyon</i> , 2020, 6, e05122.	1.4	7
23	Comparative molecular investigation of the potential inhibitors against SARS-CoV-2 main protease: a molecular docking study. <i>Journal of Biomolecular Structure and Dynamics</i> , 2020, 39, 1-7.	2.0	26
24	Current strategies against COVID-19. <i>Chinese Medicine</i> , 2020, 15, 70.	1.6	15
25	Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa241.	0.4	97
26	Comprehensive Review on Current Interventions, Diagnostics, and Nanotechnology Perspectives against SARS-CoV-2. <i>Bioconjugate Chemistry</i> , 2020, 31, 2021-2045.	1.8	58
27	Combating the Pandemic COVID-19: Clinical Trials, Therapies and Perspectives. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 606393.	1.6	21
28	Coronavirus and Homo Sapiens in Coronavirus Disease 2019 (COVID-19). <i>Journal of Cardiac Critical Care TSS</i> , 2020, 4, 121-131.	0.0	0
29	Potential Drugs and Remedies for the Treatment of COVID-19: a Critical Review. <i>Biological Procedures Online</i> , 2020, 22, 15.	1.4	22
30	&lt;p&gt;A Review on Currently Available Potential Therapeutic Options for COVID-19&lt;/p&gt;. <i>International Journal of General Medicine</i> , 2020, Volume 13, 443-467.	0.8	15
31	Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1195-1216.	1.6	28
32	Development and progress of clinical trials of Coronavirus Disease 2019 antiviral drugs. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 945-956.	1.3	3
33	A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review. <i>Life</i> , 2020, 10, 146.	1.1	6
34	Denovo designing, retrosynthetic analysis, and combinatorial synthesis of a hybrid antiviral (VTAR-01) to inhibit the interaction of SARS-CoV2 spike glycoprotein with human angiotensin-converting enzyme 2. <i>Biology Open</i> , 2020, 9, .	0.6	9
35	Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?. <i>Frontiers in Microbiology</i> , 2020, 11, 1818.	1.5	81
36	COVID-19 Outbreak: Pathogenesis, Current Therapies, and Potentials for Future Management. <i>Frontiers in Pharmacology</i> , 2020, 11, 563478.	1.6	45
37	What are the drugs having potential against COVID-19?. <i>Medicinal Chemistry Research</i> , 2020, 29, 1935-1955.	1.1	8

#	ARTICLE	IF	CITATIONS
38	Treatment Options for COVID-19: A Review. <i>Frontiers in Medicine</i> , 2020, 7, 480.	1.2	75
39	Pharmacological treatments of COVID-19. <i>Pharmacological Reports</i> , 2020, 72, 1446-1478.	1.5	35
40	A Narrative Review of Emerging Therapeutics for COVID-19. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2020, 4, 745-758.	1.2	7
41	Quadruple therapy for asymptomatic COVID-19 infection patients. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 617-624.	2.0	18
42	Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol. <i>Chinese Medical Journal</i> , 2020, 133, 1132-1134.	0.9	42
43	Medical treatment options for COVID-19. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 209-214.	0.4	39
44	Major ongoing clinical trials for COVID-19 treatment and studies currently being conducted or scheduled in Japan. <i>Global Health &amp; Medicine</i> , 2020, 2, 96-101.	0.6	20
45	Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines. <i>Military Medical Research</i> , 2020, 7, 22.	1.9	57
46	COVID-19 and Cancer: a Comprehensive Review. <i>Current Oncology Reports</i> , 2020, 22, 53.	1.8	220
47	Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines. <i>Biomedical Journal</i> , 2020, 43, 341-354.	1.4	81
48	Does lopinavir measure up in the treatment of COVID-19?. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 793-796.	1.9	6
49	Efficacy and safety of aerosol inhalation of recombinant human interferon $\beta$ 1b (IFN $\beta$ 1b) injection for noninfluenza viral pneumonia, a multicenter, randomized, double-blind, placebo-controlled trial. <i>Journal of Inflammation</i> , 2020, 17, 19.	1.5	7
50	Early risk factors of the exacerbation of coronavirus disease 2019 pneumonia. <i>Journal of Medical Virology</i> , 2020, 92, 2593-2599.	2.5	26
51	Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review. <i>Infectious Diseases and Therapy</i> , 2020, 9, 435-449.	1.8	46
52	Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets. <i>MBio</i> , 2020, 11, .	1.8	165
53	Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106055.	1.1	75
54	Possible therapeutic agents for COVID-19: a comprehensive review. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 1005-1020.	2.0	24
55	Nanotechnology for COVID-19: Therapeutics and Vaccine Research. <i>ACS Nano</i> , 2020, 14, 7760-7782.	7.3	289

#	ARTICLE	IF	CITATIONS
56	Acute Coronary Syndromes and Covid-19: Exploring the Uncertainties. <i>Journal of Clinical Medicine</i> , 2020, 9, 1683.	1.0	82
57	A comparative study on the time to achieve negative nucleic acid testing and hospital stays between danoprevir and lopinavir/ritonavir in the treatment of patients with COVID-19. <i>Journal of Medical Virology</i> , 2020, 92, 2631-2636.	2.5	23
58	Potential therapeutic agents against COVID-19: What we know so far. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 534-536.	0.6	153
59	The broad-spectrum antiviral recommendations for drug discovery against COVID-19. <i>Drug Metabolism Reviews</i> , 2020, 52, 408-424.	1.5	14
60	Overview of therapeutic drug research for COVID-19 in China. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 1133-1140.	2.8	38
61	COVID-19 infection: the China and Italy perspectives. <i>Cell Death and Disease</i> , 2020, 11, 438.	2.7	76
62	A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. <i>New England Journal of Medicine</i> , 2020, 382, 1787-1799.	13.9	4,209
63	Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment. <i>Journal of the International AIDS Society</i> , 2020, 23, e25489.	1.2	116
64	Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19. <i>Journal of Medical Virology</i> , 2020, 92, 740-746.	2.5	257
65	Virology, Epidemiology, Pathogenesis, and Control of COVID-19. <i>Viruses</i> , 2020, 12, 372.	1.5	1,091
66	The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses. <i>Frontiers in Microbiology</i> , 2020, 11, 658.	1.5	86
67	Covid-19: current knowledge, disease potential, prevention and clinical advances. <i>Turkish Journal of Biology</i> , 2020, 44, 121-131.	2.1	10
68	Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 285-299.	1.5	46
69	COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium. <i>American Journal of Transplantation</i> , 2020, 20, 3140-3148.	2.6	305
70	Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review. <i>Drug Development Research</i> , 2020, 81, 919-941.	1.4	35
71	A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease-19 treatment option. <i>Journal of Medical Virology</i> , 2020, 92, 556-563.	2.5	363
72	Audio Interview: Preparing for the Spread of Covid-19. <i>New England Journal of Medicine</i> , 2020, 382, e18.	13.9	4
73	Potential interventions for novel coronavirus in China: A systematic review. <i>Journal of Medical Virology</i> , 2020, 92, 479-490.	2.5	959

#	ARTICLE	IF	CITATIONS
74	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. <i>Lancet Respiratory Medicine</i> , 2020, 8, 506-517.	5.2	1,177
75	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic. <i>Clinical Immunology</i> , 2020, 215, 108409.	1.4	217
76	Current status of potential therapeutic candidates for the COVID-19 crisis. <i>Brain, Behavior, and Immunity</i> , 2020, 87, 59-73.	2.0	239
77	COVID-19 and therapeutic drugs repurposing in hand: The need for collaborative efforts. <i>Pharmacie Hospitalier Et Clinicien</i> , 2021, 56, 3-11.	0.3	16
78	RNA-dependent RNA polymerase of SARS-CoV-2 as a therapeutic target. <i>Journal of Medical Virology</i> , 2021, 93, 300-310.	2.5	82
79	Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19. <i>Drug Development Research</i> , 2021, 82, 12-26.	1.4	15
80	Tratamiento farmacológico de la COVID-19: revisión narrativa de los Grupos de Trabajo de Enfermedades Infecciosas y Sepsis (GTEIS) y del Grupo de Trabajo de Transfusiones Hemoderivados (GTTH). <i>Medicina Intensiva</i> , 2021, 45, 104-121.	0.4	18
81	Targeting pivotal inflammatory pathways in COVID-19: A mechanistic review. <i>European Journal of Pharmacology</i> , 2021, 890, 173620.	1.7	24
82	A comprehensive review on potential therapeutics interventions for COVID-19. <i>European Journal of Pharmacology</i> , 2021, 890, 173741.	1.7	30
83	Impact of COVID-19 in solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 925-937.	2.6	98
84	Clinical characteristics of COVID-19 patients with HIV coinfection in Wuhan, China. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 403-409.	1.0	15
86	In-silico drug repurposing study: Amprenavir, enalaprilat, and plerixafor, potential drugs for destabilizing the SARS-CoV-2 S-protein-angiotensin-converting enzyme 2 complex. <i>Results in Chemistry</i> , 2021, 3, 100094.	0.9	6
87	Computational molecular docking and virtual screening revealed promising SARS-CoV-2 drugs. <i>Precision Clinical Medicine</i> , 2021, 4, 1-16.	1.3	66
88	Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies. <i>Frontiers in Physiology</i> , 2021, 12, 593223.	1.3	113
89	Prediction of repurposed drugs for Coronaviruses using artificial intelligence and machine learning. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 3133-3148.	1.9	30
90	In silico study indicates antimalarials as direct inhibitors of SARS-CoV-2-RNA dependent RNA polymerase. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, , 1-18.	2.0	25
91	Understanding COVID-19 Pandemic: Molecular Mechanisms and Potential Therapeutic Strategies. An Evidence-Based Review. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 13-56.	1.6	33
92	A Generalized Overview of the Possible Pharmacotherapy and Treatments against SARS-CoV-2. <i>Journal of Contemporary Studies in Epidemiology and Public Health</i> , 2021, 2, ep21001.	0.1	0

#	ARTICLE	IF	CITATIONS
93	Plasma Concentrations and Safety of Lopinavir/Ritonavir in COVID-19 Patients. Therapeutic Drug Monitoring, 2021, 43, 131-135.	1.0	8
94	Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects. Frontiers in Immunology, 2020, 11, 616595.	2.2	20
95	Both Chloroquine and Lopinavir/Ritonavir Are Ineffective for COVID-19 Treatment and Combined Worsen the Pathology: A Single-Center Experience with Severely Ill Patients. BioMed Research International, 2021, 2021, 1-12.	0.9	5
96	Adjunctive Nutraceutical Therapies for COVID-19. International Journal of Molecular Sciences, 2021, 22, 1963.	1.8	33
97	A recent update on the clinical trials and effectiveness of drugs used in COVID-19, MERS and SARS Coronaviruses.. Anti-Infective Agents, 2021, 19, .	0.1	0
98	COVID-19 Pandemic: Advances in Diagnosis, Treatment, Organoid Applications and Impacts on Cancer Patient Management. Frontiers in Medicine, 2021, 8, 606755.	1.2	4
99	Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs. International Journal of Biological Macromolecules, 2021, 172, 524-541.	3.6	123
100	Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH). Medicina Intensiva (English Edition), 2021, 45, 104-121.	0.1	11
101	An Overview of Current Knowledge of Deadly CoVs and Their Interface with Innate Immunity. Viruses, 2021, 13, 560.	1.5	15
103	Pharmacotherapy for COVID-19: A Ray of Hope. , 0, , .		0
104	Nasopharyngeal Type-I Interferon for Immediately Available Prophylaxis Against Emerging Respiratory Viral Infections. Frontiers in Immunology, 2021, 12, 660298.	2.2	8
105	Clinical profile of acute pancreatitis following treatment with protease inhibitors: a real-world analysis of post-marketing surveillance data. Expert Opinion on Drug Safety, 2021, 20, 1109-1115.	1.0	5
106	O uso de Lopinavir e Ritonavir como alternativa terapêutica para a COVID-19. Research, Society and Development, 2021, 10, e43410716505.	0.0	1
107	Middle East Respiratory Syndrome (MERS) Virusâ€™ Pathophysiological Axis and the Current Treatment Strategies. AAPS PharmSciTech, 2021, 22, 173.	1.5	17
108	Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials. Journal of Infection and Public Health, 2021, 14, 740-748.	1.9	47
109	An update on emerging therapeutics to combat COVID-19. Basic and Clinical Pharmacology and Toxicology, 2021, 129, 104-129.	1.2	9
110	SARS-CoV-2: Origin, Pathogenesis and Therapeutic Interventions. Coronaviruses, 2021, 2, .	0.2	2
111	Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials. Expert Review of Anti-Infective Therapy, 2021, 19, 1219-1244.	2.0	6

#	ARTICLE	IF	CITATIONS
112	Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies. <i>European Journal of Pharmacology</i> , 2021, 906, 174248.	1.7	26
113	Therapeutic Management of COVID-19 Patients. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2022, , 210-220.	0.1	2
114	A Bioelectromagnetic Proposal Approaching the Complex Challenges of COVID-19. <i>Open Journal of Biophysics</i> , 2021, 11, 1-67.	0.7	1
115	Therapeutic Development and Drugs for the Treatment of COVID-19. <i>Medical Virology</i> , 2020, , 109-126.	2.1	21
116	Perspective on the Role of Antibodies and Potential Therapeutic Drugs to Combat COVID-19. <i>Protein Journal</i> , 2020, 39, 631-643.	0.7	3
117	COVID-19 therapy: What weapons do we bring into battle?. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115757.	1.4	22
118	Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. <i>Drug Resistance Updates</i> , 2020, 53, 100721.	6.5	80
119	Study of combining virtual screening and antiviral treatments of the Sars-CoV-2 (Covid-19). <i>Microbial Pathogenesis</i> , 2020, 146, 104241.	1.3	46
120	A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective. <i>Journal of Medical Microbiology</i> , 2017, 66, 1261-1274.	0.7	37
121	IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. <i>Journal of Clinical Investigation</i> , 2019, 129, 3625-3639.	3.9	460
122	Therapeutic strategies for critically ill patients with COVID-19. <i>Annals of Intensive Care</i> , 2020, 10, 45.	2.2	100
123	Epidemiology of CoViD-19 Pandemic: Recovery and mortality ratio around the globe. <i>Pakistan Journal of Medical Sciences</i> , 2020, 36, S79-S84.	0.3	29
124	COVID-19, Modern Pandemic: A Systematic Review From Front-Line Health Care Providersâ€™ Perspective. <i>Journal of Clinical Medicine Research</i> , 2020, 12, 215-229.	0.6	36
125	Comparative Effectiveness and Safety of Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients with Mild to Moderate Novel Coronavirus Pneumonia: Results of a Randomized, Open-Labelled Prospective Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	7
126	Therapeutic Modalities for Sars-Cov-2 (Covid-19): Current Status and Role of Protease Inhibitors to Block Viral Entry Into Host Cells. <i>Journal of Pure and Applied Microbiology</i> , 2020, 14, 1695-1703.	0.3	3
127	Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review. <i>Viruses</i> , 2020, 12, 1092.	1.5	34
130	Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-Î±1b for COVID-19. <i>Antiviral Therapy</i> , 2020, 25, 233-239.	0.6	13
131	Interim Guidelines on Antiviral Therapy for COVID-19. <i>Infection and Chemotherapy</i> , 2020, 52, 281.	1.0	29



#	ARTICLE	IF	CITATIONS
132	Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use. Indian Journal of Medical Research, 2020, 151, 184-189.	0.4	72
133	Perspectives for repurposing drugs for the coronavirus disease 2019. Indian Journal of Medical Research, 2020, 151, 160.	0.4	47
134	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future. Indian Journal of Ophthalmology, 2020, 68, 693.	0.5	78
135	The prospects of employing probiotics in combating COVID-19. Tzu Chi Medical Journal, 2022, 34, 148.	0.4	2
136	The quest for a better fight: How can nanomaterials address the current therapeutic and diagnostic obstacles in the fight against COVID-19?. Journal of Drug Delivery Science and Technology, 2022, 67, 102899.	1.4	3
140	Re-tasking the use of pre-existing medications and potential therapeutic options for coronavirus disease (COVID-19): systematic review of clinical studies. Drug Discoveries and Therapeutics, 2020, 14, 109-116.	0.6	4
141	COVID-19: A Centennial Pandemic from Origin to Clinical Trials. Acta Biologica Marisiensis, 2020, 3, 30-52.	0.1	1
142	Predictors of Severe COVID-19 Pneumonia. Journal of the Japanese Association for Infectious Diseases, 2020, 94, 483-489.	0.0	5
144	Liberty and Pandemics: A Libertarian Approach to the Global COVID-19 Situation. SSRN Electronic Journal, 0, , .	0.4	0
145	Major drugs used in COVID-19 treatment: molecular mechanisms, validation and current progress in trials. Coronaviruses, 2020, 01, .	0.2	1
146	An Overview of COVID-19: Focus on Pharmacological Aspect. SBV Journal of Basic Clinical and Applied Health Science, 2020, 3, 75-79.	0.2	0
147	Antiviral Treatment Strategies in COVID-19. International Journal of Current Research and Review (discontinued), 2020, , 23-28.	0.1	0
148	In silico comparative analysis of HIV protease inhibitors effect on 2019-nCoV coronavirus 3CLpro. Annals of Proteomics and Bioinformatics, 2020, 4, 012-014.	1.0	0
149	Coronavirus and Homo Sapiens. Journal of Cardiac Critical Care TSS, 0, , .	0.0	0
151	Therapeutic agents currently employed against Covid-19: an effort to control the pandemic. Turkish Journal of Biochemistry, 2020, 45, 651-658.	0.3	0
152	Bovine Interferon Lambda Is a Potent Antiviral Against SARS-CoV-2 Infection in vitro. Frontiers in Veterinary Science, 2020, 7, 603622.	0.9	5
153	Treatments for COVID-19: emerging drugs against the coronavirus. Acta Biomedica, 2020, 91, 118-136.	0.2	18
154	The COVID-19 pandemic and the potential treatment of the novel coronavirus SARS-CoV-2. American Journal of Translational Research (discontinued), 2021, 13, 871-881.	0.0	1

#	ARTICLE	IF	CITATIONS
155	Treatment of SARS-CoV-2 (COVID-19): A safety perspective. World Journal of Pharmacology, 2021, 10, 1-32.	1.3	1
156	Arrhythmias in COVID-19. Methodist DeBakey Cardiovascular Journal, 2021, 17, 73-82.	0.5	7
157	The Complexity of SARS-CoV-2 Infection and the COVID-19 Pandemic. Frontiers in Microbiology, 2022, 13, 789882.	1.5	20
158	Current Challenges for the Effective Management of the COVID-19 Pandemic. Advances in Experimental Medicine and Biology, 2021, 1353, 131-149.	0.8	1
159	Unraveling of inhibitory potential of phytochemicals against SARS-CoV-2 using in-silico approach. , 2022, , 471-500.		0
161	Prognosis and treatment of complications associated with COVID-19: a systematic review and meta-analysis. , 2022, 1, .		7
168	Effective Interferon Lambda Treatment Regimen To Control Lethal MERS-CoV Infection in Mice. Journal of Virology, 2022, 96, e0036422.	1.5	8
169	Camel viral diseases: Current diagnostic, therapeutic, and preventive strategies. Frontiers in Veterinary Science, 0, 9, .	0.9	8
170	The Mechanisms of Zinc Action as a Potent Anti-Viral Agent: The Clinical Therapeutic Implication in COVID-19. Antioxidants, 2022, 11, 1862.	2.2	4
171	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With Coronavirus Disease 2019 (COVID-19). Clinical Infectious Diseases, 0, , .	2.9	82
172	Middle Eastern respiratory syndrome. , 2023, , 125-172.		0
173	Lopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial. International Journal of Infectious Diseases, 2023, 128, 223-229.	1.5	7
175	COVID-19 and immunity. , 2023, , 3-32.		0